MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with SitesSOUTH SAN FRANCISCO, Calif., Dec. 11 ...
Cleveland Clinic researchers are presenting final Phase 1 data from their novel study of a vaccine aimed at preventing triple ...
Cleveland Clinic researchers are presenting final Phase I data from their novel study of a vaccine aimed at preventing triple ...
After decades of research, Phase 1 of a Cleveland Clinic study shows a breast cancer vaccine is safe and triggers an immune ...
FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient t ...
Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutation ...
Neflamapimod is an oral p38 alpha kinase inhibitor that targets dysfunction and degeneration of acetylcholine-producing ...
Southern Illinois Healthcare is expanding its cancer clinical trials program, offering patients access to advanced therapies ...
Southern Illinois Healthcare (SIH) is opening the door to some of the most advanced cancer treatments in the world, ...
Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b ...